St. Jude Medical Announces Approval And Launch Of Neurostimulation System In Japan

Main Category: Neurology / Neuroscience
Also Included In: Regulatory Affairs / Drug Approvals;  Pain / Anesthetics
Article Date: 19 Jan 2010 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


St. Jude Medical, Inc. (NYSE:STJ) announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the Genesis(TM) spinal cord stimulation system for the management of chronic pain.

Spinal cord stimulators are small implanted devices that are used for managing chronic pain of the back, arms and legs, including pain associated with back surgeries that have failed. Spinal cord stimulators - also known as neurostimulators -- deliver mild electrical pulses to leads placed in the epidural space to interrupt or mask the transmission of pain signals to the brain.

"The launch of the Genesis system in Japan is a significant step in our continued international growth," said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. "We are excited to introduce our technology in Japan and to be able to provide a new option for physicians and patients that will help them manage the severest forms of chronic pain."

The Genesis neurostimulator features:

- Compact size (28 cc) which provides physicians flexibility in placement options
- Constant current stimulation for consistent delivery of therapy
- Maximum power output of 25.5mA (~12V) to address high energy needs

Neurostimulation therapy is unique in that it provides patients with the opportunity to experience the therapy before moving forward with the permanent implant. Typically the patient undergoes a minimally invasive outpatient procedure to determine if the therapy provides adequate relief. Following this short evaluation period, the physician and patient can decide to proceed with a permanent implant.

The Genesis neurostimulator also allows patients the freedom to adjust their therapy as needed within parameters set by physicians. Each patient has a programmer that turns the system on and off and allows them to select from 24 different patient-specific customized stimulation programs, enabling them to manage their pain on a daily basis.

"Japan represents the second-largest market for medical devices in the world," said William Phillips, president of St. Jude Medical Japan. "We are excited to be able to add a neurostimulation system to the growing line of medical products that we provide to physicians to meet the varying needs of patients."

The launch of the Genesis neurostimulation system in Japan adds to the portfolio of products available to physicians from St. Jude Medical Japan. Others include:

- Cardiac Rhythm Management devices for the treatment of abnormal heart rhythms and heart failure (ZephyrTM pacemaker, FrontierTM II CRT-P, CurrentTM Implantable Cardioverter Defibrillator [ICD], PromoteTM Cardiac Resynchronization Therapy Defibrillator [CRT-D], IsoFlexTM Pacing Leads, TendrilTM ST OptimTM Pacing Lead, DurataTM Defibrillation Lead, and others)

- Products within the Atrial Fibrillation Division which aid physicians in accessing, diagnosing and treating cardiac arrhythmias (EnsiteTM 3D Cardiac Mapping System, InquiryTM Diagnostic Catheter IBI Ablation Catheter, SwartzTM Braided Introducer, AgilisTM NxT Introducer, and others)

- Cardiology products for the diagnoses and treatment of cardiovascular and valvular disease (SJM RegentTM Mechanical Heart Valve, SJM Rigid Saddle Ring, SJM TailorTM Ring+Band, Angio-SealTM Evolution Vascular Closure Device, SignetTM Pro PTCA Balloon Catheter, PressureWireTM, Certus FFR Measurement System, and others)

Chronic pain is a largely under-treated and misunderstood condition that affects millions of patients worldwide. The World Health Organization, in conjunction with the International Association for the Study of Pain (IASP), reports that as many as one in five people suffers from moderate to severe chronic pain.

More than 60,000 patients in 35 countries have been implanted with St. Jude Medical neurostimulation systems. Patients can obtain more information about neurostimulation therapy at http://www.PowerOverYourPain.com.

Source
St. Jude Medical

Article adapted by Medical News Today from original press release.
Visit our neurology / neuroscience section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
St. Jude Medical. "St. Jude Medical Announces Approval And Launch Of Neurostimulation System In Japan." Medical News Today. MediLexicon, Intl., 19 Jan. 2010. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/176371.php>

APA
St. Jude Medical. (2010, January 19). "St. Jude Medical Announces Approval And Launch Of Neurostimulation System In Japan." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/176371.php.

Please note: If no author information is provided, the source is cited instead.


Neurology / Neuroscience

Most Popular Articles



Follow Our Neurology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Neurology / Neuroscience Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »